Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 710-717

  Bianchi, Roberto ^a   Gilardini, Alessandra ^b   Rodriguez Menendez, Virginia ^b   Oggioni, Norberto ^b   Canta, Annalisa ^b   Colombo, Tina ^a   Michele, Giulia De ^a   Martone, Sara ^a   Sfacteria, Alessandra ^c   Piedemonte, Giuseppe ^c   Grasso, Giovanni ^d   Beccaglia, Patrizia ^e   Ghezzi, Pietro ^a   D'Incalci, Maurizio ^a   Lauria, Giuseppe ^f   Cavaletti, Guido ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e Janssen Cilag SpA Italia   (Italy)

^f IRCCS Scientific Institute of Milan   (Italy)

Author keywords

Cisplatin; Erythropoietin; Neurophysiology; Pathology; Peripheral neuropathy; Rat; Tumour growth

Indexed keywords

CISPLATIN; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HINDLIMB; MAMMARY NEOPLASMS, EXPERIMENTAL; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, WISTAR;

EID: 33947703740     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.09.028     Document Type: Article

References (53)

1. Henry D.H., Bowers P., Romano M.T., and Provenzano R. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 164 3 (2004) 262-276
2. Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 42 2 (2003) 142-149
3. Erbayraktar S., Yilmaz O., Gokmen N., and Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2 6 (2003) 465-470
4. Weiss M.J. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist 8 Suppl 3 (2003) 18-29
5. Campana W.M., and Myers R.R. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur J Neurosci 18 6 (2003) 1497-1506
6. Campana W.M., and Myers R.R. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. Faseb J 15 10 (2001) 1804-1806
7. Ehrenreich H., Aust C., Krampe H., et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 19 3-4 (2004) 195-206
8. Marti H.H. Erythropoietin and the hypoxic brain. J Exp Biol 207 Pt 18 (2004) 3233-3242
9. Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol 31 1 (2004) 129-142
10. Genc S., Koroglu T.F., and Genc K. Erythropoietin and the nervous system. Brain Res 1000 1-2 (2004) 19-31
11. Buemi M., Cavallaro E., Floccari F., et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 62 3 (2003) 228-236
12. Wojchowski D.M., Gregory R.C., Miller C.P., Pandit A.K., and Pircher T.J. Signal transduction in the erythropoietin receptor system. Exp Cell Res 253 1 (1999) 143-156
13. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 5681 (2004) 239-242
14. Keswani S.C., Buldanlioglu U., Fischer A., et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 56 6 (2004) 815-826
15. Bianchi R., Buyukakilli B., Brines M., et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101 3 (2004) 823-828
16. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 1 (2002) 9-17
17. Barajon I., Bersani M., Quartu M., et al. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol 138 1 (1996) 93-104
18. Cavaletti G., Tredici G., Marmiroli P., et al. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 84 4 (1992) 364-371
19. Cavaletti G., Minoia C., Schieppati M., and Tredici G. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 29 4 (1994) 771-776
20. Cavaletti G., Tredici G., Marmiroli P., Fabbrica D., and Braga M. Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. In Vivo 8 3 (1994) 313-316
21. Tredici G., Tredici S., Fabbrica D., Minoia C., and Cavaletti G. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J Neurooncol 36 1 (1998) 31-40
22. Tredici G., Cavaletti G., Petruccioli M.G., et al. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology 15 3 (1994) 701-704
23. Orhan B., Yalcin S., Nurlu G., Zeybek D., and Muftuoglu S. Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats. Med Oncol 21 2 (2004) 197-203
24. Bianchi R., Brines M., Lauria G., et al. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 12 8 (2006) 2607-2612
25. Tacey R., Greway A., Smiell J., et al. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods 283 1-2 (2003) 317-329
26. Pisano C., Pratesi G., Laccabue D., et al. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9 15 (2003) 5756-5767
27. Genc S., Koroglu T.F., and Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 22 2 (2004) 105-119
28. Chong Z.Z., Kang J.Q., and Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 3 2 (2003) 141-154
29. Lewis L.D. Preclinical and clinical studies: a preview of potential future applications of erythropoietic agents. Semin Hematol 41 4 Suppl 7 (2004) 17-25
30. Gabrilove J.L. Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes. Semin Hematol 38 3 Suppl 7 (2001) 1-7
31. Umapathi T., and Chaudhry V. Toxic neuropathy. Curr Opin Neurol 18 5 (2005) 574-580
32. Armstrong T., Almadrones L., and Gilbert M.R. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 32 2 (2005) 305-311
33. Forman A.D. Peripheral neuropathy and cancer. Curr Oncol Rep 6 1 (2004) 20-25
34. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest 21 3 (2003) 439-451
35. Verstappen C.C., Heimans J.J., Hoekman K., and Postma T.J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63 15 (2003) 1549-1563
36. Corbo M., and Balmaceda C. Peripheral neuropathy in cancer patients. Cancer Invest 19 4 (2001) 369-382
37. Meijer C., de Vries E.G., Marmiroli P., et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20 6 (1999) 883-887
38. Cece R., Petruccioli M.G., Cavaletti G., Barajon I., and Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol 10 4 (1995) 837-845
39. Cece R., Petruccioli M.G., Pizzini G., Cavaletti G., and Tredici G. Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. J Submicrosc Cytol Pathol 27 4 (1995) 417-425
40. Cavaletti G., Pezzoni G., Pisano C., et al. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett 322 2 (2002) 103-106
41. Tredici G., Braga M., Nicolini G., et al. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 159 2 (1999) 551-558
42. Mollman J.E. Cisplatin neurotoxicity. N Engl J Med 322 2 (1990) 126-127
43. Krarup-Hansen A., Rietz B., Krarup C., et al. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 25 1 (1999) 29-40
44. Gregg R.W., Molepo J.M., Monpetit V.J., et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10 5 (1992) 795-803
45. Hovestadt A., van der Burg M.E., Verbiest H.B., van Putten W.L., and Vecht C.J. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol 239 3 (1992) 143-146
46. Schratzberger P., Walter D.H., Rittig K., et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 107 9 (2001) 1083-1092
47. Tillmann H.C., Kuhn B., Kranzlin B., et al. Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 69 1 (2006) 60-67
48. Masunaga H., Takahira R., Hirabayashi M., and Sawai T. Pharmacodynamics and therapeutic usage of recombinant human erythropoietin (SNB-5001) in animal models. Nippon Yakurigaku Zasshi 99 4 (1992) 213-229
49. Djulbegovic B. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best Pract Res Clin Haematol 18 3 (2005) 455-466
50. Glaspy J., and Dunst J. Can erythropoietin therapy improve survival?. Oncology 67 Suppl 1 (2004) 5-11
51. Bohlius J., Langensiepen S., Schwarzer G., et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97 7 (2005) 489-498
52. Kilpatrick T.J., Phan S., Reardon K., Lopes E.C., and Cheema S.S. Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat. Brain Res 911 2 (2001) 163-167
53. Davis I.D., Kiers L., MacGregor L., et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11 5 (2005) 1890-1898